The analyst underlines the good operating momentum but indicates that there is no new information on the proposed asset demerger.

UBS confirms its buy recommendation on the stock and its price target of E15.2, which represents a potential upside of 48%.

' Vivendi reported organic growth of +2.6% for FY 2023, with EBITA slightly ahead of expectations. Havas posted organic growth of +4.7% in Q4 2023. No new information on the proposed demerger' says the research firm.

The group reported net income, group share of 405 million euros in 2023 (0.40 euro per basic share), compared with a loss of 1,010 million euros in 2022 (-0.98 euro per basic share), an increase of 1,415 million euros.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.